Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629905 | 0.90 | LPAR1 (0.46) | LPAR1LPAR5MAOBSCN9ASCN3A | |
| SCHEMBL4630536 | 0.90 | LPAR1 (0.51) | LPAR1LPAR5FFAR1FFAR4MAOB | |
| SCHEMBL5316248 | 0.89 | LPAR1 (0.41) | LPAR1LPAR5MAPTFFAR1FFAR4 | |
| SCHEMBL3996243 | 0.88 | TP53 (0.48) | LPAR1LPAR5MAPTMAOBTSPO | |
| SCHEMBL4764980 | 0.85 | FFAR4 (0.43) | POLBMAPTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL4631046 | 0.83 | PPARG (0.42) | POLBMAPTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL4001008 | 0.80 | ALDH1A1 (0.46) | POLBMAPTSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL4965244 | 0.80 | MAPT (0.46) | MAPTTSPONPC1 | |
| Amantadine SCHEMBL5311412 | 0.80 | LPAR1 (0.42) | LPAR1LPAR5FFAR1FFAR4MAOB | |
| SCHEMBL4629897 | 0.80 | LPAR1 (0.53) | LPAR1LPAR5MAOBSCN9ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517883-B8 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| US-7355069-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1517883-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1517883-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | GPR119, INSR, IRS1 | LPAR1 2995/4885LPAR5 3941/4885POLB 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.